[go: up one dir, main page]

AR119080A1 - Proteínas multiespecíficas - Google Patents

Proteínas multiespecíficas

Info

Publication number
AR119080A1
AR119080A1 ARP200101567A ARP200101567A AR119080A1 AR 119080 A1 AR119080 A1 AR 119080A1 AR P200101567 A ARP200101567 A AR P200101567A AR P200101567 A ARP200101567 A AR P200101567A AR 119080 A1 AR119080 A1 AR 119080A1
Authority
AR
Argentina
Prior art keywords
domain
specifically binds
ankyrin repeat
ankyrin
serum albumin
Prior art date
Application number
ARP200101567A
Other languages
English (en)
Inventor
Christian Reichen
Alexander Link
Julia Hepp
Victor Levitsky
Original Assignee
Molecular Partners Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners Ag filed Critical Molecular Partners Ag
Publication of AR119080A1 publication Critical patent/AR119080A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cell Biology (AREA)

Abstract

Esta divulgación se refiere a proteínas recombinantes multiespecíficas útiles para el tratamiento de cáncer. Reivindicación 1: Una proteína recombinante que comprende: un primer dominio de repetición de anquirina que se une específicamente a proteína de activación de fibroblastos (FAP), un segundo dominio de repetición de anquirina que se une específicamente a 4-1BB, un tercer dominio de repetición de anquirina que se une específicamente a 4-1BB, un cuarto dominio de repetición de anquirina que se une específicamente a albúmina sérica y un quinto dominio de repetición de anquirina que se une específicamente a albúmina sérica, en la que dichos dominios de repetición de anquirina están dispuestos, desde el extremo N-terminal hasta el extremo C-terminal, según la siguiente fórmula: (dominio de unión a albúmina sérica) - (dominio de unión a FAP) - (dominio de unión a 4-1BB) - (dominio de unión a 4-1BB) - (dominio de unión a albúmina sérica).
ARP200101567A 2019-06-04 2020-06-03 Proteínas multiespecíficas AR119080A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962857037P 2019-06-04 2019-06-04

Publications (1)

Publication Number Publication Date
AR119080A1 true AR119080A1 (es) 2021-11-24

Family

ID=71069894

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101567A AR119080A1 (es) 2019-06-04 2020-06-03 Proteínas multiespecíficas

Country Status (17)

Country Link
US (2) US20200385488A1 (es)
EP (1) EP3980443A1 (es)
JP (1) JP2022535564A (es)
KR (1) KR20220016945A (es)
CN (1) CN114206943A (es)
AR (1) AR119080A1 (es)
AU (1) AU2020289080A1 (es)
BR (1) BR112021024236A2 (es)
CA (1) CA3139051A1 (es)
CO (1) CO2021017845A2 (es)
IL (1) IL288613A (es)
MX (1) MX2021014286A (es)
PH (1) PH12021553000A1 (es)
SG (1) SG11202112921VA (es)
TW (1) TW202112804A (es)
UY (1) UY38739A (es)
WO (1) WO2020245746A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021116469A2 (en) 2019-12-11 2021-06-17 Molecular Partners Ag Recombinant peptide-mhc complex binding proteins and their generation and use
EP4146691A1 (en) 2020-05-06 2023-03-15 Molecular Partners AG Novel ankyrin repeat binding proteins and their uses
JP2023528204A (ja) 2020-05-14 2023-07-04 モレキュラー パートナーズ アクチェンゲゼルシャフト 多選択性タンパク質
CN116390937A (zh) 2020-08-11 2023-07-04 治纳辅医药科技有限公司 一种包含il-12和抗cd20抗体的融合蛋白及其应用
US11981710B2 (en) 2020-08-18 2024-05-14 Athebio Ag N-terminal capping modules of ankyrin repeat domains
EP3957649A1 (en) * 2020-08-18 2022-02-23 Athebio AG Improved n-terminal capping modules of ankyrin repeat domains
EP4304731A1 (en) 2021-03-09 2024-01-17 Molecular Partners AG Novel darpin based multi-specific t-cell engagers
CN115197329A (zh) * 2021-04-13 2022-10-18 晶源生物医药(苏州)有限公司 一种4-1bb激动剂及其制备方法和应用
WO2022219185A1 (en) * 2021-04-16 2022-10-20 Athebio Ag N-terminal capping modules of ankyrin repeat domains
WO2023121890A1 (en) * 2021-12-23 2023-06-29 Fbd Biologics Limited Cd47/4-1bb-targeting protein complex and methods of use thereof
MX2024009564A (es) 2022-02-11 2024-08-19 Kanaph Therapeutics Inc Composicion farmaceutica para tratamiento de cancer que comprende proteina de fusion que incluye il-12 y anticuerpo anti-fap, y uso de la misma.
KR20230162310A (ko) 2022-05-20 2023-11-28 주식회사 카나프테라퓨틱스 Light 단백질 및 항-fap 항체를 포함하는 융합단백질 및 이의 용도
EP4565606A1 (en) 2022-08-01 2025-06-11 Molecular Partners AG Charge modified designed repeat domains and their use
WO2024037743A1 (en) * 2022-08-16 2024-02-22 Athebio Ag Variants of ankyrin repeat domains
WO2023194628A2 (en) * 2022-08-16 2023-10-12 Athebio Ag Variants of ankyrin repeat domains
EP4673159A1 (en) 2023-02-27 2026-01-07 Molecular Partners AG Darpins for use in reducing renal accumulation of drugs

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
CA2421447C (en) 2000-09-08 2012-05-08 Universitat Zurich Collections of repeat proteins comprising repeat modules
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
ES2836948T3 (es) 2008-11-03 2021-06-28 Molecular Partners Ag Proteínas de unión que inhiben la interacción del receptor de VEGF-A
AU2010301105A1 (en) 2009-10-02 2012-04-19 Ludwig Institute For Cancer Research Ltd. Anti-fibroblast activation protein antibodies and methods and uses thereof
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
MY177065A (en) 2010-09-09 2020-09-03 Pfizer 4-1bb binding molecules
CA2818969C (en) 2010-11-26 2020-04-14 Molecular Partners Ag Improved n-terminal capping modules for designed ankyrin repeat proteins
KR20150023957A (ko) 2012-06-28 2015-03-05 몰리큘라 파트너스 아게 혈소판-유래 성장인자에 결합하는 설계된 안키린 반복 단백질
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
CN105209483B (zh) 2013-05-31 2021-07-27 分子组合公司 与肝细胞生长因子结合的设计锚蛋白重复蛋白
US20170247455A1 (en) 2014-08-22 2017-08-31 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
DK3489256T3 (da) 2014-11-14 2021-05-25 Hoffmann La Roche Antigenbindende molekyler omfattende en TNF-familieligandtrimer
CN107454904A (zh) * 2015-04-02 2017-12-08 分子组合公司 对血清白蛋白具有结合特异性的经设计的锚蛋白重复结构域
EP3356403A2 (en) * 2015-10-02 2018-08-08 H. Hoffnabb-La Roche Ag Bispecific antibodies specific for a costimulatory tnf receptor
MY193013A (en) * 2015-10-07 2022-09-22 Hoffmann La Roche Bispecific antibodies with tetravalency for a costimulatory tnf receptor
US10717772B2 (en) 2016-09-22 2020-07-21 Molecular Partners Ag Recombinant binding proteins targeting HER2 and serum albumin, and their uses

Also Published As

Publication number Publication date
SG11202112921VA (en) 2021-12-30
US20200385488A1 (en) 2020-12-10
JP2022535564A (ja) 2022-08-09
MX2021014286A (es) 2022-01-06
EP3980443A1 (en) 2022-04-13
CN114206943A (zh) 2022-03-18
WO2020245746A1 (en) 2020-12-10
PH12021553000A1 (en) 2023-08-23
KR20220016945A (ko) 2022-02-10
BR112021024236A2 (pt) 2022-04-26
IL288613A (en) 2022-02-01
TW202112804A (zh) 2021-04-01
CA3139051A1 (en) 2020-12-10
CO2021017845A2 (es) 2022-01-17
UY38739A (es) 2020-12-31
US20240190999A1 (en) 2024-06-13
AU2020289080A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
AR119080A1 (es) Proteínas multiespecíficas
PE20191463A1 (es) Anticuerpos biespecificos de union especifica pd1 y lag3
NZ724904A (en) Hybrid immunoglobulin containing non-peptidyl linkage
ES2676023T3 (es) Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso
PE20191551A1 (es) Polipeptidos de union al receptor de transferrina disenados
PE20191033A1 (es) PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
AR060017A1 (es) Composiciones y metodos de uso para anticuerpos de dickkopf -1
PE20190352A1 (es) Proteinas de fusion gdf 15 y usos de estas
PE20100054A1 (es) Inmunoglobulina con dominio variable dual
MX2022015847A (es) Proteinas de union a cd123 y composiciones y metodos relacionados.
AR074399A1 (es) Moleculas biespecificas de union a egfr/igfir
MX2018000697A (es) Peptidos anti-inflamatorios y usos de los mismos.
BR112018003594A2 (pt) cadeia pesada de imunoglobulina recombinante, anticorpos, método de produção de conjugado e conjugados
CA2648109A1 (en) Combination of an anti-ed-b fibronectin domain antibody-il-2 fusion protein and gemcitabine
PE20091713A1 (es) Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos
EA201791238A1 (ru) Способы и композиции, в которых используются варианты полипептидов klotho
PE20181890A1 (es) Contorsbody - un ligante de diana monocatenario
MX2009003126A (es) Agente para prevenir/tratar el cancer.
PH12022551828A1 (en) Multispecific antibodies, compositions comprising the same, and vectors and uses thereof
ZA202000961B (en) Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
PE20181956A1 (es) Polipeptidos que inhiben cd40l
EA201391005A1 (ru) Слитый белок против злокачественной опухоли
BR112013013548B8 (pt) Proteína de fusão anticancerígena
EA201790341A1 (ru) Анти-ск8 антитела для применения в лечении рака
PE20221051A1 (es) Proteinas de fusion terapeuticas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal